Search | Clinical Trials Finder

Conditions: Liver Cirrhosis, Biliary
Interventions: INT-747, Ursodeoxycholic Acid (URSO), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Primary Biliary Cirrhosis
Interventions: rituximab; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions: [18F]FP-R01-MG-F2; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Biliary Cirrhosis
Interventions: Pentoxifylline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 76 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Biliary Cholangitis
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions: Vancomycin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LB-P8 low-dose, LB-P8 high-dose, Placebo; Drug
Lead sponsor: LISCure Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: LUM001; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Sclerosing Cholangitis
Interventions: Fecal Microbiota Transplantation; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cholangitis, Sclerosing
Interventions: Oral all-trans retinoic acid (ATRA); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Rochester, Minnesota

Conditions: Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cholestatic Pruritus
Interventions: CR845 1.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Coronado, California • Rialto, California • San Francisco, California + 10 more

Conditions: Primary Biliary Cholangitis
Interventions: Saroglitazar magnesium 1 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Marietta, Georgia • Indianapolis, Indiana • Houston, Texas

Conditions: Primary Biliary Cirrhosis (PBC)
Interventions: Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 16 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Cilofexor, Placebo to match cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 16
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Primary Biliary Cirrhosis
Interventions: NGM282, Placebo; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor 80 mg, Elafibranor 120 mg, Placebo; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Curcumin; Drug
Lead sponsor: John E. Eaton; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Biliary Cirrhosis
Interventions: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle); Drug
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Gainesville, Florida • Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis
Interventions: DUR-928; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: SpyGlass DS I - II; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Davis, California • Sacramento, California • Salt Lake City, Utah

Conditions: Primary Sclerosing Cholangitis
Interventions: PLN-74809, Placebo; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Pasadena, California • Redwood City, California • Sacramento, California + 17 more

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

Pentoxifylline for Primary Biliary Cirrhosis

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

Use of Fenofibrate for Primary Biliary Cirrhosis

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity